Aigen Investment Management LP boosted its holdings in shares of Guardant Health, Inc. (NASDAQ:GH - Free Report) by 35.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 25,957 shares of the company's stock after purchasing an additional 6,854 shares during the quarter. Aigen Investment Management LP's holdings in Guardant Health were worth $793,000 as of its most recent SEC filing.
A number of other hedge funds also recently bought and sold shares of GH. Lord Abbett & CO. LLC purchased a new stake in shares of Guardant Health in the third quarter valued at $15,624,000. Guyasuta Investment Advisors Inc. purchased a new stake in shares of Guardant Health in the fourth quarter valued at $206,000. Cerity Partners LLC raised its stake in shares of Guardant Health by 54.6% in the third quarter. Cerity Partners LLC now owns 195,008 shares of the company's stock valued at $4,473,000 after acquiring an additional 68,883 shares during the period. Geode Capital Management LLC increased its stake in Guardant Health by 1.1% in the 3rd quarter. Geode Capital Management LLC now owns 2,822,220 shares of the company's stock worth $64,754,000 after buying an additional 29,686 shares during the period. Finally, Entropy Technologies LP purchased a new position in Guardant Health in the 4th quarter worth about $377,000. Hedge funds and other institutional investors own 92.60% of the company's stock.
Analyst Ratings Changes
Several research analysts recently commented on the stock. Piper Sandler raised their price target on shares of Guardant Health from $34.00 to $50.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 26th. Raymond James reaffirmed an "outperform" rating and issued a $59.00 price target (up previously from $39.00) on shares of Guardant Health in a research note on Friday, February 21st. Morgan Stanley raised their price target on shares of Guardant Health from $42.00 to $52.00 and gave the stock an "overweight" rating in a research note on Thursday. Barclays assumed coverage on shares of Guardant Health in a research note on Thursday, January 23rd. They issued an "overweight" rating and a $60.00 price target on the stock. Finally, Scotiabank raised their price target on shares of Guardant Health from $47.00 to $52.00 and gave the stock a "sector outperform" rating in a research note on Monday, February 24th. Twenty investment analysts have rated the stock with a buy rating, According to MarketBeat, Guardant Health presently has a consensus rating of "Buy" and a consensus target price of $48.40.
Read Our Latest Stock Report on GH
Guardant Health Trading Down 2.1 %
Shares of NASDAQ:GH traded down $0.85 during trading on Friday, reaching $39.32. The stock had a trading volume of 2,314,557 shares, compared to its average volume of 2,476,829. Guardant Health, Inc. has a one year low of $15.81 and a one year high of $50.89. The company has a market capitalization of $4.85 billion, a P/E ratio of -11.04 and a beta of 1.50. The firm's 50-day simple moving average is $42.06 and its 200 day simple moving average is $32.46.
Guardant Health (NASDAQ:GH - Get Free Report) last released its quarterly earnings results on Thursday, February 20th. The company reported ($0.90) earnings per share for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.15). The firm had revenue of $201.81 million during the quarter, compared to the consensus estimate of $192.50 million. Guardant Health had a negative net margin of 59.05% and a negative return on equity of 19,157.20%. Equities research analysts forecast that Guardant Health, Inc. will post -2.9 earnings per share for the current fiscal year.
Insider Buying and Selling
In related news, Director Musa Tariq sold 2,320 shares of Guardant Health stock in a transaction that occurred on Friday, December 13th. The shares were sold at an average price of $35.00, for a total value of $81,200.00. Following the completion of the sale, the director now directly owns 2,676 shares in the company, valued at $93,660. This trade represents a 46.44 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders sold 2,668 shares of company stock worth $95,208 in the last three months. Corporate insiders own 5.50% of the company's stock.
About Guardant Health
(
Free Report)
Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.
See Also
Before you consider Guardant Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Guardant Health wasn't on the list.
While Guardant Health currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
